Edge Rewrite
location Source code View original
// request.cf · coarse context

A page that knows where it met you.

Only coarse request metadata is shown. This demo does not display or persist visitor IP addresses.

Country
US
Cloudflare location
CMH
Connection
HTTP/2
Language
Not provided

Ray ID: a2864b9dc817f689

Jump to content

AB-300

Add links
From Wikipedia, the free encyclopedia
AB-300
Clinical data
Other namesAB300; Ariadne Bio-300
Drug classNon-hallucinogenic serotonin 5-HT2A and 5-HT2C receptor agonist

AB-300, short for Ariadne Bio-300, is a non-hallucinogenic serotonin 5-HT2A and 5-HT2C receptor agonist which is under development for potential medical use to treat non-motor symptoms of Parkinson's disease such as apathy and motivational deficits as well as late-life depression.[1][2][3]

It has been found to reverse motivational deficits induced by the dopamine depleting agent tetrabenazine and hence to produce pro-motivational effects in rodents.[1] These effects were more pronounced in rodents with the lowest baseline motivation and were comparable to those of the norepinephrine–dopamine reuptake inhibitor (NDRI) bupropion.[1] Bupropion has psychostimulant-like effects in rodents, but not at typical clinical doses in humans.[4][5][6]

AB-300 is under development by Ariadne Bio, a company of Negev Labs.[1][2][3] Ariadne Bio is named after Ariadne (4C-D; BL-3912; Dimoxamine), a non-hallucinogenic serotonin 5-HT2A receptor agonist which was developed by Alexander Shulgin and Bristol Laboratories, produced indirect dopaminergic and pro-motivational effects in animals analogously to AB-300, and reached phase 3 clinical trials for various medical uses in the 1970s, but was ultimately never marketed due to cited strategic economic reasons.[7][8][9][10] A phase 1b trial of AB-300 is initiating in the third quarter of 2026.[2][3] The exact chemical structure of AB-300 does not yet appear to have been disclosed, but it is said to have been patented.[1][2]

See also

[edit]

References

[edit]
  1. 1 2 3 4 5 Jeffries, Daniel (May 2026). AB-300, a novel 5-HT2A/2C agonist, reverses motivational deficits in a tetrabenazine model of Parkinson's disease apathy. 2026 ASCP Annual Meeting. Miami Beach, Florida: American Society of Clinical Psychopharmacology. Retrieved 9 August 2026.
  2. 1 2 3 4 "Ariadne Bio". Ariadne Bio. Retrieved 9 August 2026. Ariadne Bio is the first company from Negev Labs, [...] AB-300 is designed to activate 5-HT2A without hallucinogenic effect, potentially making it an accessible and self-administered therapy for motivational deficits. [...] Patented. Randomized, placebo-controlled Phase 1b trial in Parkinson's disease patients with clinically significant apathy. [...] Phase 1b clinical trial initiating Q3 2026
  3. 1 2 3 Negev Labs. "CNS & Brain Health Therapeutics Venture Fund". Negev Capital. Retrieved 9 August 2026. Ariadne Bio is developing AB-300, a first-in-class non-hallucinogenic 5-HT2A agonist designed to treat apathy in Parkinson's disease, late-life depression, and neurodegeneration [...] Phase 1b trial initiation targeted for Q3 2026. [...] Stage Preclinical → Phase 1b Q3 2026 · Modality Non-hallucinogenic 5-HT2A agonist · Indication Apathy in Parkinson's / late-life depression
  4. ↑ Mori T, Shibasaki M, Ogawa Y, Hokazono M, Wang TC, Rahmadi M, Suzuki T (October 2013). "Comparison of the behavioral effects of bupropion and psychostimulants". Eur J Pharmacol. 718 (1–3): 370–375. doi:10.1016/j.ejphar.2013.07.046. PMID 23993950.
  5. ↑ Naglich AC, Brown ES, Adinoff B (2019). "Systematic review of preclinical, clinical, and post-marketing evidence of bupropion misuse potential". Am J Drug Alcohol Abuse. 45 (4): 341–354. doi:10.1080/00952990.2018.1545023. PMID 30601027.
  6. ↑ Dwoskin LP, Rauhut AS, King-Pospisil KA, Bardo MT (2006). "Review of the pharmacology and clinical profile of bupropion, an antidepressant and tobacco use cessation agent". CNS Drug Rev. 12 (3–4): 178–207. doi:10.1111/j.1527-3458.2006.00178.x. PMC 6506196. PMID 17227286.
  7. ↑ Cunningham MJ, Bock HA, Serrano IC, Bechand B, Vidyadhara DJ, Bonniwell EM, Lankri D, Duggan P, Nazarova AL, Cao AB, Calkins MM, Khirsariya P, Hwu C, Katritch V, Chandra SS, McCorvy JD, Sames D (January 2023). "Pharmacological Mechanism of the Non-hallucinogenic 5-HT2A Agonist Ariadne and Analogs". ACS Chemical Neuroscience. 14 (1): 119–135. doi:10.1021/acschemneuro.2c00597. PMC 10147382. PMID 36521179.
  8. ↑ Shulgin, Alexander; Shulgin, Ann (September 1991). PiHKAL: A Chemical Love Story. Berkeley, California: Transform Press. ISBN 0-9630096-0-5. OCLC 25627628.
  9. ↑ Shulgin A, Manning T, Daley PF (2011). "#7. ARIADNE". The Shulgin Index, Volume One: Psychedelic Phenethylamines and Related Compounds. Vol. 1. Berkeley, CA: Transform Press. pp. 7–9. ISBN 978-0-9630096-3-0. OCLC 709667010.
  10. ↑ Shulgin AT (1987). "The "Social-Chemistry" of Pharmacological Discovery: Interview with Dr. Alexander T. Shulgin. January 26, 1986". Social Pharmacology. 1 (3): 279–290. Archived from the original on 12 July 2025.
[edit]
Retrieved from "https://en.wikipedia.org/w/index.php?title=AB-300&oldid=1368489271"